CJC-1295 DAC: The Long-Acting GHRH Analog
"CJC-1295 DAC" and "CJC-1295 + Ipamorelin" get used interchangeably, but they describe two different things: a single GHRH analog with a drug-affinity complex versus a co-formulated vial that pairs a GHRH analog with a selective growth-hormone secretagogue. This guide untangles the two, walks through what the component evidence does and doesn't establish, and covers how researchers can verify a 5mg/5mg blend vial before sourcing it.
Update History ▾
Research-use-only framing applied throughout in line with Remy editorial standards.
CJC-1295 DAC is one molecule; the CJC-1295 + Ipamorelin blend is a co-formulation of a GHRH analog with a selective secretagogue — so the comparison is really about formulation and evidence, not which one is "stronger." Remy Peptides currently lists CJC-1295 + Ipamorelin 5mg/5mg Vial as In stock, with 10mg total · Lyophilized research vial; see the product page for current pricing. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
What CJC-1295 DAC Is
The naming alone causes confusion. People searching cjc 1295 dac are often after the long-acting GHRH analog on its own, while searches for cjc ipamorelin or the cjc-1295 + ipamorelin blend usually mean the two-peptide research vial — CJC-1295 (a GHRH analog) paired with Ipamorelin (a selective GHRP). The sections below walk through each component's identity, what the published research actually supports, where the blend evidence runs out, and how researchers can verify a supplier before buying.
The "DAC" in CJC-1295 DAC is a drug-affinity complex: the modified GRF(1-29) peptide is conjugated to a group that binds circulating albumin, and that albumin binding is what turns a short-lived GHRH fragment into a long-acting analog.[4] In healthy adults, single doses of CJC-1295 produced prolonged, dose-dependent increases in growth hormone and IGF-1 measured over several days,[1] and growth-hormone secretion stayed pulsatile during continuous stimulation rather than flattening out.[5] CJC-1295 without DAC — the bare mod-GRF(1-29) peptide — omits that albumin-binding complex, which is the practical distinction most researchers are trying to pin down.
For current product facts, start with CJC-1295 + Ipamorelin 5mg/5mg Vial.
Evidence Map and Translation Limits
CJC-1295 is a long-acting GHRH analog studied for prolonged GH and IGF-1 secretion, while Ipamorelin is described in early literature as a selective growth-hormone secretagogue.[1][2] The blend-rationale discussion should remain a research-design concept, because published human data on the exact Remy-style co-formulated vial are limited.[3]
| Research layer | What the literature supports | What it means for sourcing |
|---|---|---|
| CJC-1295 component | The CJC-1295 literature centers on GHRH analog design, albumin-binding extension, and prolonged endocrine signal measurement. | Confirm the vial names CJC-1295 as a distinct component, not just "DAC." |
| Ipamorelin component | Ipamorelin literature focuses on ghrelin-pathway secretagogue selectivity and model-level endocrine signaling. | Explains why it sits alongside a GHRH analog in the blend — a different mechanism, not a duplicate. |
| Blend evidence limit | Component data do not equal clinical validation for a fixed 5mg/5mg research blend. | Treat the 5mg/5mg ratio as a research-design choice, not proven synergy. |
Where Remy Peptides Supplies CJC-1295
Remy Peptides does not list a standalone CJC-1295 DAC vial. CJC-1295 is supplied as a component of the in-stock CJC-1295 + Ipamorelin 5mg/5mg research vial — see that product page for current format, stock, pricing, and COA route. Check the COA library for available documentation. For in-vitro laboratory research only; not for human or veterinary use.
Supplier Checks for Research-Use Buyers
For research-supply searches, the cleanest buying checklist is evidence-light and verification-heavy. Before comparing any CJC-1295 + Ipamorelin source, confirm:
- The seller gives a stable product URL with vial size, format, price tier, and stock status.
- The page states Research Use Only and avoids human-use, veterinary-use, diagnostic, therapeutic, or disease-management claims.
- The listing states the >99% HPLC line standard and an identity method (mass spec) for the compound.
- Cold-chain handling and official-contact verification are clear enough to reduce impersonation and gray-market risk.
Remy Peptides centralizes that workflow through the product page, the COA library, and contact verification.
What This Page Does Not Claim
The research record helps define the compound, but it does not turn an RUO vial into a clinical product. Keep these boundaries in view:
- Do not present the blend as an anti-aging, muscle, recovery, or hormone-optimization product.
- Do not include timing schedules, dosing charts, or administration routes.
- Separate DAC terminology from the exact Remy blend format.
Our Research Standards
This guide draws on the Remy CJC-1295 and Ipamorelin research, live product-catalog data, and peer-reviewed and official sources. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →
CJC-1295 DAC Research FAQ
What is CJC-1295 DAC?
CJC-1295 DAC is a long-acting analog of growth-hormone-releasing hormone (GHRH): a modified GRF(1-29) peptide conjugated to a drug-affinity complex that binds serum albumin, which extends its activity to a duration measured in days. It is a research compound, not an approved medicine.
How does CJC-1295 DAC differ from CJC-1295 without DAC?
The DAC version carries the albumin-binding drug-affinity complex, which makes it long-acting. CJC-1295 without DAC is the bare mod-GRF(1-29) peptide, which lacks that complex — that is the practical distinction most researchers are trying to resolve.
What does the human evidence on CJC-1295 DAC show?
In healthy adults, single doses produced prolonged, dose-dependent increases in growth hormone and IGF-1 measured over several days, and growth-hormone secretion stayed pulsatile during continuous stimulation. The published record is early-phase and preclinical; there is no large obesity or anti-aging outcome program.
Does Remy Peptides sell standalone CJC-1295 DAC?
No. Remy supplies CJC-1295 as a component of the in-stock CJC-1295 + Ipamorelin 5mg/5mg research vial, not as a separate DAC-only product. See that product page for current format, stock, and COA.
Is CJC-1295 DAC for human or veterinary use?
No. Remy Peptides products are supplied strictly for in-vitro laboratory research. They are not for human use, veterinary use, diagnosis, treatment, cure, disease management, or personal-use protocols.
Sources
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006. PMID: 16352683 ↑
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822 ↑
- Kojima M, Kangawa K. Ghrelin: structure and function. PMC4443295 ↑
- Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi: 10.1210/en.2004-1286 ↑
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi: 10.1210/jc.2006-1702 ↑
For current stock, pricing, and COA route, use the live CJC-1295 + Ipamorelin 5mg/5mg Vial page. For wider supplier verification, continue to the peptide COA guide and official contact verification.